Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …
Pathophysiological mechanisms of thrombosis in acute and long COVID-19
H Jing, X Wu, M Xiang, L Liu, VA Novakovic… - Frontiers in …, 2022 - frontiersin.org
COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …
CytoSIP: an annotated structural atlas for interactions involving cytokines or cytokine receptors
L Wang, F Sun, Q Li, H Ma, J Zhong, H Zhang… - Communications …, 2024 - nature.com
Therapeutic agents targeting cytokine-cytokine receptor (CK-CKR) interactions lead to the
disruption in cellular signaling and are effective in treating many diseases including tumors …
disruption in cellular signaling and are effective in treating many diseases including tumors …
Estimating Time Window to Administer Anti-Cytokine Therapeutic Drugs to COVID-19 Patients
The severe COVID-19 infection often leads to “Cytokine Release Syndrome (CRS)”, which is
a serious adverse medical condition causing multiple organ failures. Anti-cytokine therapy …
a serious adverse medical condition causing multiple organ failures. Anti-cytokine therapy …